• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Castle Biosciences Inc.

    2/27/25 4:13:12 PM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email
    S-8 1 forms-8x2019equityincentiv.htm S-8 Document

    As filed with the Securities and Exchange Commission on February 27, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    Castle Biosciences, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware77-0701774
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    505 S. Friendswood Drive, Suite 401
    Friendswood, Texas
    77546
    (Address of Principal Executive Offices)(Zip Code)

    Castle Biosciences, Inc. 2019 Equity Incentive Plan
    Castle Biosciences, Inc. 2019 Employee Stock Purchase Plan
    (Full titles of the plans)
    Derek J. Maetzold
    President and Chief Executive Officer
    Castle Biosciences, Inc.
    505 S. Friendswood Drive, Suite 401
    Friendswood, Texas 77546
    (866) 788-9907
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    Copies to:
    Thomas A. Coll, Esq.
    Carlos Ramirez, Esq.
    Cooley LLP
    10265 Science Center Drive
    San Diego, California 92121
    (858) 550-6000
    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated fileroAccelerated filerx
    Non-accelerated fileroSmaller reporting companyo
    Emerging growth companyo
    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o



    EXPLANATORY NOTE
    This Registration Statement on Form S-8 is being filed by Castle Biosciences, Inc. (the “Registrant”) for the purpose of registering (i) an additional 1,424,159 shares of the Registrant’s Common Stock, $0.001 par value per share (“Common Stock”), under the Registrant’s 2019 Equity Incentive Plan (the “2019 Plan”), pursuant to the provisions of the 2019 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2019 Plan, and (ii) 284,831 additional shares of Common Stock under the Registrant’s 2019 Employee Stock Purchase Plan (the “2019 ESPP”) pursuant to the provisions of the 2019 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2019 ESPP, in each case on January 1, 2025.

    INCORPORATION OF DOCUMENTS BY REFERENCE
    This Registration Statement is being filed for the purpose of registering additional securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective.
    The Registrant previously registered shares of its Common Stock for issuance under the 2019 Plan and 2019 ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on July 29, 2019 (File No. 333-232884), March 10, 2020 (File No. 333-237062), March 11, 2021 (File No. 333-254179), February 28, 2022 (File No. 333-263094), February 28, 2023 (File No. 333-270141) and February 28, 2024 (File No. 333-277472). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.




    ITEM 8. EXHIBITS.
    Exhibit Number
    Description
    4.1
    Amended and Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on July 29, 2019.
    4.2
    Amended and Restated Bylaws of the Registrant, incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on July 29, 2019.
    4.3
    Form of Common Stock Certificate of the Registrant. incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-232369), originally filed with the SEC on June 26, 2019, as amended.
    4.4
    Sixth Amended and Restated Investors’ Rights Agreement, dated July 12, 2019, by and among the Registrant and certain of its stockholders, incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-232369), as amended, originally filed with the SEC on July 15, 2019.
    5.1*
    Opinion of Cooley LLP.
    23.1*
    Consent of KPMG LLP, Independent Registered Public Accounting Firm.
    23.2*
    Consent of Cooley LLP. Reference is made to Exhibit 5.1.
    24.1*
    Power of Attorney. Reference is made to the signature page hereto.
    99.1
    Castle Biosciences, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-232884), filed with the SEC on July 29, 2019.
    99.2
    Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2019 Plan, incorporated by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1 (File No. 333-232369), originally filed with the SEC on June 26, 2019, as amended.
    99.3
    Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q, filed with SEC on November 9, 2020.
    99.4
    Castle Biosciences, Inc. 2019 Employee Stock Purchase Plan, incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form S-1 (File No. 333-232369), originally filed with the SEC on June 26, 2019, as amended.
    107*
    Filing Fee Table
    __________________________________
    *    Filed herewith.




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Friendswood, State of Texas, on February 27, 2025.
    CASTLE BIOSCIENCES, INC.
    By:/s/ Derek J. Maetzold
    Derek J. Maetzold
    President and Chief Executive Officer

    POWER OF ATTORNEY
    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Derek J. Maetzold and Frank Stokes, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.



    Signature
    Title
    Date
    /s/ Derek J. Maetzold
    President, Chief Executive Officer and Director
    February 27, 2025
    Derek J. Maetzold
    (Principal Executive Officer)
    /s/ Frank Stokes
    Chief Financial Officer
    February 27, 2025
    Frank Stokes
    (Principal Financial and Accounting Officer)
    /s/ Daniel M. BradburyChairperson of the Board of DirectorsFebruary 27, 2025
    Daniel M. Bradbury
    /s/ Kimberlee S. CapleMember of the Board of DirectorsFebruary 27, 2025
    Kimberlee S. Caple
    /s/ G. Bradley ColeMember of the Board of DirectorsFebruary 27, 2025
    G. Bradley Cole
    /s/ Rodney CottonMember of the Board of DirectorsFebruary 27, 2025
    Rodney Cotton
    /s/ Ellen GoldbergMember of the Board of DirectorsFebruary 27, 2025
    Ellen Goldberg
    /s/ Miles D. HarrisonMember of the Board of DirectorsFebruary 27, 2025
    Miles D. Harrison
    /s/ Tiffany P. OlsonMember of the Board of DirectorsFebruary 27, 2025
    Tiffany P. Olson


    Get the next $CSTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.

    SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    1/21/26 1:21:12 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

    1/13/26 9:43:02 AM ET
    $CSTL
    Medical Specialities
    Health Care

    SEC Form 144 filed by Castle Biosciences Inc.

    144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    1/5/26 5:09:12 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

    FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company's website: htt

    2/5/26 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

    2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025. "We are extremely pleased with our excellent fourth quarter and ful

    1/11/26 4:00:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting c

    12/19/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Exec. Officer Maetzold Derek J sold $158,757 worth of shares (4,017 units at $39.52), decreasing direct ownership by 5% to 83,698 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    2/5/26 4:17:22 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J sold $160,732 worth of shares (4,017 units at $40.01), decreasing direct ownership by 4% to 87,715 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    1/22/26 4:15:22 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J was granted 62,219 shares, increasing direct ownership by 211% to 91,732 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    1/14/26 4:30:11 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Castle Biosciences with a new price target

    Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

    12/14/23 6:54:55 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Castle Biosciences with a new price target

    Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

    1/5/23 7:53:37 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Stephens & Co. initiated coverage on Castle Biosciences with a new price target

    Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

    1/7/22 5:42:05 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Financials

    Live finance-specific insights

    View All

    Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

    FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company's website: htt

    2/5/26 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Reports Third Quarter 2025 Results

    Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company's test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that

    11/3/25 4:07:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

    FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2025, after the close of market on Monday, Nov. 3, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/153584002, or via the webcast link on the Investor Relations page of the Company's website:

    10/13/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    View All

    Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

    The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

    4/30/24 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

    -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

    10/23/23 8:00:00 AM ET
    $CSTL
    $EQ
    $ICPT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

    SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

    5/26/21 12:42:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/14/24 4:40:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/13/24 6:44:33 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    7/8/24 4:32:39 PM ET
    $CSTL
    Medical Specialities
    Health Care